Resolution

Gemeinsamer Bundesausschuss

of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII – Amendment of Information on the Period of Validity of a Resolution on the Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V Apalutamide

of 20 February 2020

At its session on 20 February 2020, the Federal Joint Committee (G-BA) resolved to amend the Directive on the Prescription of Medicinal Products in SHI-accredited Medical Care (Pharmaceuticals Directive, AM-RL) in the version dated 18 December 2008 / 22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), last amended on D Month YYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

I. In Annex XII, the provision under Section II Number 2 concerning the period of validity of the resolution on the benefit assessment apalutamide of 1 August 2019 shall be amended as follows:

The entry “15 May 2020” will be replaced by “1 April 2020”.

II. The resolution will enter into force with effect from the day of its publication on the internet on the website of the G-BA on 20 February 2020.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 20 February 2020

Federal Joint Committee
in accordance with Section 91 SGB V
The Chair

Prof. Hecken